We are revolutionizing drug discovery with a disruptive platform based on high-resolution mass spectrometry (HRMS) instruments aiming to outperform DNA-encoded library (DEL) and structure-based drug design (SBDD) technologies. Our technology retains the scalability of these traditional methods while overcoming their limitations by directly measuring receptor–drug interactions using HRMS instruments. Our technology enables faster and more accurate identification of drug candidates with higher clinical relevance to reduce risk and accelerate the path from discovery to development.
Our vision is to pioneer the discovery and delivery of innovative therapeutics for challenging targets and diseases through our novel technology platform. We are dedicated to pushing the boundaries of what's possible in drug development and especially focus on diseases areas where conventional approaches fall short. We aim to discover new pathways and identify effective treatments to ultimately bring life-changing medicines to patients suffering from complex and underserved conditions.
Our mission is to transform how new medicines are discovered by building a technology platform that experimentally and directly measures interactions between biological receptors and drug molecules. Our technology enables drug screening from complex natural drug sources to identify effective treatments from regions of chemical space inaccessible to traditional methods.